OncoImmunology

Advances in Adoptive Cell Therapies

Adoptive cell therapies (ACT) have recently taken center stage in cancer immunotherapy, largely due to the success of chimeric antigen receptor (CAR-T) cell therapies in treating hematologic malignancies. In ACT, patient immune cells are collected, engineered ex vivo to strengthen anti-tumor immunity, expanded, and then infused back into the patient. From infusions of tumor-infiltrating lymphocytes (TIL) to the development of T-cell receptor (TCR)-T and chimeric antigen receptor (CAR)-T cell therapies, adoptive cell therapies show much promise for revolutionizing cancer care.

There remain many challenges to bringing these techniques into the clinic, including the time and labor-intensive manufacturing process as well the need to enhance persistence and tumor infiltration, to address severe toxicity, to overcome antigen escape, and to investigate combination therapies and optimal treatment sequencing. Use of ACTs in solid tumors faces the formidable challenge of immunosuppressive microenvironments and antigen heterogeneity. New strategies are emerging to overcome these hurdles and to advance cell therapy.

This Article Collection seeks papers focused on pre-clinical, translational, and clinical research on ACT, including but not limited to:

• Efficacy, Safety and Toxicity Management of existing products

• Combination Approaches & Maximizing ACT Efficacy

• Emerging technologies, such as CRISPR-edited T cells, CAR-NK, TCR-NK, and universal CAR platforms.

• Personalized approaches and biomarkers: understanding patient-specific factors influencing ACT response and identifying predictive biomarkers.

• Improving production and manufacturing

•Overcoming challenges specific to solid tumors

• Pharmacoeconomic implications of ACT

Dr. Falchi earned his MD degree Cum Laude and a board certification in Medical Oncology Cum Laude at the University of Perugia, Italy. He subsequently completed a postdoctoral fellowship at MD Anderson Cancer Center in Houston, TX, a medicine residency at Yale-New Haven Hospital in New Haven, CT, and a Hematology/Oncology fellowship at Columbia University Irving Medical Center in New York, NY. He is board certified in Internal Medicine, Hematology and Medical Oncology. He currently holds a dual appointment as Assistant Attending in the Lymphoma Service and Cellular Therapy Service at Memorial Sloan Kettering Cancer Center and is an Assistant Professor of Medicine at Weill Cornell Medical College, both in New York, NY. Dr. Falchi’s areas of expertise include non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma. His current research is focused on the use of immunotherapy for the treatment of patients with B-cell NHL through the conduct of clinical and translational studies. He is the lead investigator in multiple national and global immunotherapy trials for patients with B-cell NHL. He authored or co-authored over 95 articles published in high-impact peer-reviewed journals, including The Lancet, Journal of Clinical Oncology, The Lancet Oncology, Blood, and Annals of Oncology, as well as numerous abstracts and several book chapters. Dr. Falchi is Co-Editor-In-Chief of Oncoimmunology and serves as peer-reviewer for numerous high-profile journals, such as JAMA, the Journal of Clinical Oncology, Blood and JAMA Oncology. He is recipient of several awards including the Blood Cancer United Scholar in Clinical Research award and the Lymphoma Research Foundation Career Development award. He has served on committees of the American Society of Clinical Oncology and Society for Immunotherapy of Cancer and is an active member of multiple scientific societies, including the American Society of Hematology, the American Society of Clinical Oncology, American Medical Association, the American Association for Cancer Research.

Disclosure Statement: Dr. Falchi declares: Research funding from Roche, Genentech, Genmab, AbbVie, Innate Pharma, BeiOne medicines, Astrazeneca; Consultancy for Roche, Genentech, Genmab, AbbVie, Sanofi, Astrazeneca, Merck, NOBO medicine; Honoraria from Roche, Genmab, AbbVie, Kite, Chugai; Travel Support from Genmab, AbbVie, Roche, Kite, Chugai and is on the Advisory Board for AbbVie, Genentech, Genmab, ADC therapeutics (Seagen), (Ipsen), Johnson & Johnson, Regeneron, Chugai, Bristol Myers Squibb.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31st December 2026.

Please contact Rebecca Turner at rebecca.turner@tandf.co.uk with any questions or requests for discount codes relating to this Article Collection.

Please be sure to select the appropriate Article Collection from the drop-down menu in the submission system.